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Abstract. Gastric cancer (GC) is the fourth most common 
cause of cancer‑associated death. Based on the age at diagnosis, 
GC is divided into early‑onset GC (EOGC; ≤45 years) and 
conventional GC (CGC; >45 years). Mutations in the cell cycle 
checkpoint kinase 2 (CHEK2) and TP53 genes are associated 
with several types of cancer; however, their genetic defects in 
GC remain poorly understood. The aim of the present study 
was to determine the subcellular distribution of the CHEK2 
protein and its redistribution following DNA damage, to 
improve the understanding of the DNA damage response. 
Genetic alterations and patterns of expression of CHEK2 and 
p53 proteins were investigated to identify potential biological 
markers and indicators of GC development. Additionally, the 
affected signaling pathways and their clinical importance 
in GC development and associated syndromes were investi‑
gated. A total of 196 GC samples (89 CGC and 107 EOGC 
samples) were used in the present study. DNA from 53 samples 
(18 CGC and 35 EOGC samples) was sequenced using 
targeted next‑generation sequencing technology to identify 
and compare common and rare mutations associated with GC. 
Subsequently, the cytoplasmic and nuclear expression levels of 
CHEK2, phosphorylated (p)‑CHEK2 at threonine 68 and p53 
in GC tissues were determined via immunohistochemistry. 
Sequencing resulted in the identification of 63 single nucleotide 
polymorphisms (SNPs) in the CHEK2 gene amongst 5 different 
variants, and the intron variant c.319+379A>G was the most 
common SNP. In the TP53 gene, 57 different alterations were 
detected amongst 9 variant types, and the missense variant 
c.215C>G was the most common. Nuclear CHEK2 expression 
was high in both the EOGC and CGC subtypes. However, 
the prevalence of cytoplasmic CHEK2 expression (P<0.001) 
and nuclear p‑CHEK2 expression (P=0.011) was significantly 
higher in CGC compared with in EOGC tissues. There was 
a statistically significant difference between high and low 
cytoplasmic CHEK2 expression in patients with p53‑positive 
EOGC compared with in patients with p53‑positive CGC 
(P=0.002). The present study was designed to determine the 
association between CHEK2 and p53 expression patterns in 
patients with EOGC and CGC, as well as genetic alterations in 
the CHEK2 and TP53 genes.
Introduction
Gastric cancer (GC) is the fourth most common cause of 
cancer‑related death worldwide (1). The incidence of GC 
increases with age, and the median age at diagnosis is 
70 years (2). However, ~10% of the gastric carcinomas are 
detected at the age of 45 or younger (3). GC is a multifacto‑
rial disease, and both environmental and genetic factors serve 
a role in its etiology (2‑4). GC in younger patients is termed 
early‑onset gastric cancer (EOGC), and is likely caused by 
a predisposing genotype that facilitates the development of 
the cancer due to various environmental triggers (4). It has 
been postulated that genetic factors may be more important 
in EOGC than in elder patients, as younger patients have a 
shorter duration of exposure to environmental carcinogens (3).
Currently, there are two distinguished classifications of GC, 
the World Health Organization (WHO) and the Laurén classifi‑
cation system. According to the Laurén classification, which is 
often used for diversification, there are two histological subtypes: 
Diffuse and intestinal (5). Intestinal gastric carcinoma is more 
common in elder patients and it is frequently accompanied 
by multifocal atrophic gastritis. This is followed by intestinal 
metaplasia and leads to cancer via dysplasia. Younger patients 
more commonly exhibit a diffuse cancer, in which hereditary 
factors serve a major role in the development.
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DNA damage response genes are involved in the preserva‑
tion of a healthy genome. Defects in cell cycle checkpoints and 
DNA repair genes, such as ATM, CHEK2, BRCA1, BRCA2 and 
TP53, particularly mutations and/or aberrant downregulation, 
may be associated with the development of gastric cancer (6).
The cell cycle checkpoint kinase 2 (CHEK2) gene serves 
a significant role in the DNA damage response signaling 
network, particularly in cancer development (7). Germline 
mutations in the gene have been reported in families of patients 
with cancer; particularly for breast cancer (8‑10) and prostate 
cancer (11,12), but also in other types of cancer (7,13,14), 
including gastric cancer (15). The most prevalent mutant 
alleles of CHEK2 are three mutant alleles resulting in protein 
truncation (1100delC, IVS2G>A, del5395), one which is a 
missense variant (I157T) (16).
In humans, the CHEK2 protein is a 65 kDa polypeptide 
that consists of 543 amino acids and three different functional 
domains. The N terminal SQ/TQ cluster domain contains a 
region rich in serine‑glutamine and threonine‑glutamine 
motifs, which are potential sites of phosphorylation by ATR 
and ATM kinases (part of the PI3K family) (17). Under physi‑
ological conditions, CHEK2 in retained in the nucleus in an 
inactive, monomeric form. DNA damage initiates phosphoryla‑
tion at Thr68 and other sites of the SQ/TQ cluster domain. The 
phosphorylated site binds to the forkhead‑associated domain 
and forms a dimer that is further activated by autophosphory‑
lation at the C‑terminal serine/threonine kinase domain (18). 
As a result, the dimer dissociates into fully active monomers. 
The Thr68 phosphorylated form of CHEK2 creates distinct 
nuclear foci as a reaction to ionizing radiation (19). Only the 
activated form of CHEK2 is present at sites of DNA double 
stranded breaks. These observations suggest that CHEK2 is 
regulated at the site of the DNA double stranded break, and 
that phosphorylated CHEK2 has an important role in the 
DNA damage response. Our current study is focused on both 
forms of CHEK2 to examine their role in the development of 
age‑dependent subtypes of gastric carcinoma.
The TP53 gene is located on the short arm of chromosome 
17 (17p13.1) (18). Multiple studies have demonstrated the 
genetic association between TP53 alterations and cancer 
susceptibility. The TP53 gene is the most frequently mutated 
gene (>50%) in human cancer, suggesting that the TP53 gene 
serves a pivotal role in preventing the formation of cancer (19). 
In gastric carcinoma the mutations are located broadly across a 
gene, from exons 4‑11 with hot spots of mutations at codons 175, 
248, 273, 282, 245 and 213. Additionally, G:C>A:T transitions 
at CpG sites are the most popular types of mutation (20).
The p53 protein serves an important role in regulation or 
cancer progression through the regulation of apoptosis, the 
cell cycle and genomic stability (21). p53 can stimulate DNA 
repair proteins when DNA damage is persistent or serious. 
It can prevent proliferation by arresting the cell cycle at the 
G1/S regulation point following recognition of DNA damage. 
When a cell is arrested at this checkpoint, the DNA repair 
proteins attempt a repair. However, if the cells are arrested at 
this checkpoint for a sufficient amount of time, the cell may 
instead undergo apoptosis (22).
The present study focused on the frequency of genetic 
alterations in the CHEK2 and TP53 genes, and the expression 
patterns of the phosphorylated and non‑phosphorylated 
CHEK2 and p53 proteins in both conventional (C)GC and 
early onset (EO)GC, to assess the effects of CHEK2 and p53 
in the development of the heterogeneous nature of GC.
Materials and methods
Patients. The tissue samples used in the present study 
included 89 cases of CGC, diagnosed between 1993‑2003 
and 107 samples of EOGC, obtained from the Academic 
Medical Centre in Amsterdam as well as collected from 
24 institutions in the Netherlands, Finland and Poland. Tumor 
samples were classified according using the Laurén clas‑
sification system (23) as either intestinal or diffuse gastric 
adenocarcinomas (Table I). The tissues were previously used 
for a previous analysis (24), where immunohistochemical 
labelling was performed to determine the expression patterns 
of several gastric cancer markers amongst EOGC and CGC. 
For sequencing analysis, 53 GC tissues were selected, 35 with 
EOGC and 18 with CGC, taking into consideration the DNA 
quality status of the samples. The present study was approved 
by the Medical University of Lublin Bioethical Committee 
and was performed in accordance with the Declaration of 
Helsinki.
DNA extraction. Tissues were obtained as previously 
described by Sitarz et al (25). Genomic DNA extraction 
from formalin‑fixed paraffin‑embedded (FFPE) tissues was 
performed using the QIAamp DNA Mini kit (Qiagen GmbH) 
or a Puregene DNA Isolation kit (Gentra, Inc.) in accordance 
with the manufacturers' protocols. DNA was quantified using 
a Quantus™ Fluorometer with the QuantiFluor® dsDNA 
system according to the manufacturer's protocol (Promega 
Corporation). DNA quality was assessed using an Agilent 
2200 TapeStation and Genomic DNA ScreenTape (Agilent 
Technologies, Inc.). Further evaluation of the suitability of 
the samples for sequencing was performed using an Infinium 
HD FFPE QC assay protocol (Illumina, Inc.). The Real‑Time 
PCR using a CFX96 Touch™ Real‑Time PCR Detection 
system (Bio‑Rad Laboratories, Inc.) was used to assess the 
amplification status of each sample.
Library preparation using a target enrichment workflow for 
next generation sequencing. Libraries for the sequencing 
experiments were prepared using a Trusight Rapid Capture 
Preparation kit (Illumina, Inc.) according to the manufac‑
turer's protocol. DNA samples were standardized to 50 ng and 
underwent a tagmentation step. The produced libraries from 
input of genomic DNA were amplified and adapter tagged 
multiple short library fragments of 220‑350 base pairs were 
prepared. Libraries for each sample were combined to ensure 
proper complexity for a single run. Biotin labelled probes 
were used to target regions of interest. Further hybridiza‑
tion steps were performed using custom synthesized oligos 
that captured genes with an assigned predisposition towards 
multiple cancer types. The sequencing panel, TruSight Cancer 
Panel (Illumina, Inc.), targeted 94 genes and 284 SNPs linked 
to common and rare cancers. The complete list of target genes 
and SNPs is available from illumina.com/techniques/popular‑ 
applications/genotyping.html. Standard pools were enriched 
with regions of interest through streptavidin coated beads that 
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bound to the biotinylated probes. Then, DNA fragments were 
eluted from the beads and another round of hybridization and 
enrichment was performed. The final amplified post‑capture 
library concentrations were assessed using a Quantus™ 
Fluorometer according to the manufacturer's protocol. 
Libraries were quantified by qPCR using a KAPA Library 
Quantification kit (KAPA Biosystems, Inc.). The size of the 
obtained libraries fragments was evaluated using an Agilent 
2200 TapeStation and High Sensitivity D1000 ScreenTape 
system (Agilent Technologies, Inc.). Post capture enriched 
libraries were sequenced on a MiSeq Sequencing Platform 
(Illumina, Inc.) using the manufacturer's workflow. The 
concentration of loaded libraries amounted to 10 pM. The 
sequencing experiments were performed using a MiSeq 
Reagent kit version 2 (300 cycles).
Data processing. Results from each sample were mapped to 
the human reference genome GRCh37, also known as hg19 
(Human Genome version 19) using Burrows‑Wheeler Aligner 
(BWA‑mem, version 0.7.5). The reads with low mapping 
quality scores, unmapped reads and duplicates were filtered 
out using Samtools version 0.1.19 (26). Local realignment of 
reads around indels (insertion or deletion) and detection of 
systematic errors in base quality scores were performed using 
Genome Analysis Toolkit (27). The reads mapped outside the 
target region were removed. Variant calling for germline SNPs 
and indels was performed using the GATK HaplotypeCaller 
tool (28). The call sets of SNPs and small insertions and 
deletions were separated for further filtering. Hard filters 
applied to variant call sets for SNPs were, QualByDepth 
(QD)<2.0, RMSMappingQuality (MQ)<40.0, FisherStrand 
(FS)>60.0, HaplotypeScore>13.0, QRankSum<‑12.5 
and ReadPosRankSum<‑8.0; and for INDELs, QD<2.0, 
ReadPosRankSum<‑20.0, FS>200.0. Filtered variants were 
concatenated into one record (VCF file) and the discovered 
variants were annotated with SnpEff (version 4.2) using 
GEnome MINIng (Gemini) version 0.18.3, and loaded into an 
SQLite database (29). 
Immunohistochemistry. CHEK2 immunohistochemical 
staining was performed using a mouse monoclonal antibody 
for CHEK2 (Santa Cruz Biotechnology, Inc.; cat. no. sc5278; 
1:200; incubation period 1 h), a rabbit monoclonal antibody 
against p‑CHEK2 (Thr68; Cell Signaling Technology, 
Inc.; cat. no. 2197; 1:50; ARS pH 9; 72 h incubation at 4˚C). 
The sections (4 µm) were deparaffinized and endogenous 
peroxidase activity was blocked by immersion in 0.3% H2O2 
and in methanol for 20 min. Antigen retrieval was performed 
in sodium citrate/ARS buffer (0.01 M/pH 6.0) for 10 min 
at 120˚C or in Tris/EDTA buffer (10 mM/1 mM; pH 9.0) 
for 10 min at 120˚C. Subsequently, once the samples had 
cooled for 10 min, they were washed in PBS and blocked 
using PBS with 5% normal goat serum. Then the material 
was incubated with the antibodies. Antibody binding was 
visualized using a Powervision + poly‑HRP detection system 
(Leica Microsystems; cat. no. PV6107) with Bright DAB 
(Immunologic; cat. no. BS04‑110) as the chromogen for 
CHEK2, and PowerDAB (Immunologic; cat. no. BS03‑25) 
used as the chromogen for p‑CHEK2. Sections were 
counterstained using hematoxylin.
TP53 staining; sections (4‑µm thick) were deparaffinized 
and antigen retrieval was performed by boiling in 10 mM 
Tris/1 mM EDTA (pH 9.0) for 10 min. Subsequently, slides 
were immersed in 0.3% hydrogen peroxide in methanol for 
30 min and nonspecific binding was blocked with 5% normal 
goat serum for 1 h at room temperature. The sections were 
incubated for 1 h at room temperature with an anti‑p53 
antibody (monoclonal antibody combination of DO‑7 and 
BP53‑12; Neomarkers, Inc.; 1:2,000). The Ultravision 
anti‑polyvalent HRP detection system (Lab Vision Corp.) was 
used to visualize antibody binding with 3,30‑diaminobenzi‑
dine used as the chromogen. Sections were counterstained 
using hematoxylin.
Scoring. Scoring of immunohistochemistry was performed for 
analysis of CHEK2 and p53 expression. Scoring was performed 
independently by two researchers, any disagreements in 
score were reanalyzed by the expert using a multiheaded 
microscopes in accordance with his judgement. Cases where 
the staining was not clearly abnormal were categorized into 
the normal group. No slides exhibited increased negative 
staining around the edges, and the age of the block had no 
impact on immunohistochemical staining. Multiple scoring 
systems in the literature were considered to ensure a system 
that adequately reflected the results generated was used, and 
all cases were re‑examined based on the agreed upon scoring 
parameters.
Immunohistochemical labelling revealed the patterns of 
CHEK2 and p‑CHEK2 expression in GC (Fig. 1). The scoring 
criteria for the quantity of the tumor cells were: 1, No staining; 
2, weak staining (≤10% of the cancer cells); 3, moderate 
staining (10‑50% of the cancer cells); 4, strong staining (nuclear 
staining in >50% of the cancer cells). For statistical analysis, 
scores 0 and 1 were categorized as ‘CHEK2 low staining’ 
and scores 2 and 3 as ‘CHEK2 high staining’. The following 
scoring system was used for p53: Cases scored as positive 
showed strong nuclear staining in >30% of cells, whereas 
normal mucosa showed scant staining in the proliferative 
zone only.
Statistical analysis. Statistical analysis (including immuno‑
histochemistry staining of CHEK2 and p‑CHEK2 proteins, 
immunohistochemical staining of p53 and association between 
the genetic alterations of CHEK2 and TP53 genes and their 
Table I. Histological types of GC samples analyzed in the 
study (n=196).
 Early‑onset GC Conventional GC
Characteristic (n=107) (n=89)
Age (range), years ≤45 (21‑45) >45 (47‑86)
Histology, n (%)  
  Intestinal 21 (20) 42 (47)
  Diffuse 78 (73) 37 (42)
  Mixed 8 (7) 10 (11)
GC, gastric cancer.
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protein expression levels) were performed using the χ2 test. 
For this purpose we used GraphPad programme and applied 
the 2x2 contingency table. We chose chi‑square test with the 
Yates' continuity correction, which is designed to make the 
chi‑square approximation better. We calculated two‑tailed 
(also called two‑sided) P‑values. P<0.05 was considered to 
indicate a statistically significant difference.
Results
CHEK2 genetic alterations amongst EOGC and CGC. 
Next‑generation sequencing results were generated for 
53 patients with GC, 35 patients with EOGC and 18 patients 
with CGC. DNA from all samples was successfully amplified, 
libraries were constructed and a minimum coverage amongst 
regions of interest was obtained in all tested samples. Results 
from next‑generation targeted sequencing for CHEK2 are 
shown in Table II. A total of 5 different variants in CHEK2 
were found amongst 53 cases: 2 missense variants, 2 synony‑
mous variants and 1 intron alteration. The c.1741G>T missense 
alteration in CHEK2 was observed only in one case and was 
described as a medium impact mutation, according to Gemini. 
This variant seemed to be very rare, as it had not been previ‑
ously described in CHEK2 and has never been reported in 
NCBI ClinVar or dbSNP (Table SI). Both missense variants: 
c.1246A>G (medium) and the synonymous variant: c.1245C>T 
(low) were detected in 5 out of 53 cases. The CHEK2 c.252A>G 
synonymous variant, which according to NCBI ClinVar 
database, is associated with a hereditary predisposition to 
colorectal cancer and familial breast cancer, was detected in 
5 cases. Interestingly the intron variant c.319+379A>G was 
detected in 47 cases, but according to Gemini, its impact was 
low. The detected mutations are fairly uncommon for gastric 
carcinoma; they were not found in Catalogue of Somatic 
Mutations in Cancer (COSMIC).
TP53 genetic alterations amongst EOGC and CGC. Results 
from next‑generation sequencing for TP53 are shown in 
Table III. A total of 9 variant alterations in TP53 were detected 
in 53 patients: 5 missense variants, 2 synonymous vari‑
ants, 1 frameshift variant and 1 premature stop codon. The 
c.1129A>C missense variant was found in one case (EOGC, 
1 HET‑heterozygote) and was described as a medium impact 
mutation, according to Gemini (Table SII), and present in 
dbSNP and ClinVar where it was described to be associated 
with Li‑Fraumeni syndrome, but not present in the COSMIC 
database. The c.1014C>T synonymous variant was present in 
1 EOGC case as heterozygous, was considered a low impact 
alteration, described in clinical repositories as related to 
hereditary cancer predisposing syndrome and Li‑Fraumeni 
syndrome, and in COSMIC it was described as being related 
to skin and upper aerodigestive tract. A deletion (frameshift 
variant): c.851_852delCA was observed in one CGC case, 
described as high impact, and was considered as rare as it was 
not described in any of the databases. The missense alteration 
c.844C>G was reported in 1 EOGC case, as heterozygous, 
was considered medium impact and was associated with 
hereditary cancer predisposing syndrome, and in COSMIC, it 
was described as being associated with lung and breast cancer, 
as well as hematopoietic and lymphoid, upper aerodigestive 
tract and pancreatic neoplastic disease. This alteration was 
also found in stomach cancer by Rugge et al (30) and by 
Xu et al (31). 
Missense variant c.818G>A was found in one patient 
with CGC, as heterozygous, medium impact, related to 
Li‑Fraumeni syndrome, thyroid cancer and hereditary cancer 
predisposing syndrome according to the ClinVar database; 
and according to COSMIC, it was found in multiple studies 
in stomach cancer, but predominantly in large intestine, 
breast, lung, central nervous system and ovary cancer. 
Variant c.734G>A was a missense alteration, found in one 
Figure 1. Immunohistochemical staining of CHEK2 and p‑CHEK2 in gastric cancer tissues (magnification, x100). The following scoring criteria of the tumor 
cells were used: 0+, no staining; 1+, weak diffuse cytoplasmic staining (may contain stronger intensity in <10% of the cancer cells); 2+, moderate to strong 
cytoplasmic staining in 10‑50% of the cells; 3+, >50% of the tumor cells stained with strong intensity. p‑CHEK2, phosphorylated checkpoint kinase 2.
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case (CGC, 1 HET) and was described as a medium impact 
mutation, described in dbSNP and ClinVar as associated with 
Li‑Fraumeni syndrome and hereditary cancer predisposing 
syndrome. In the COSMIC database, it was shown to be found 
in large intestine, esophagus, hematopoietic and lymphoid, 
lung and breast neoplasms. In cancers of the stomach, the 
variant was previously reported by Gleeson et al (32) and 
Kim et al (33).
Interestingly, variant c.639A>G (synonymous) was found 
in 3 CGC cases and 1 EOGC case as heterozygous. This 
was a low impact variant, associated with hereditary cancer 
predisposing syndrome and Li‑Fraumeni syndrome, and 
was not found in stomach cancer previously according to 
COSMIC. However it had been detected in large intestine, 
soft tissue and central nervous system neoplasms. The variant 
causing an introduction of premature stop codon, c.586C>T 
was considered high impact and was detected in one CGC 
case (HET), associated with hereditary cancer predisposing 
syndrome and Li‑Fraumeni syndrome; and in the COSMIC 
database was described to be associated with large intestine, 
breast, esophagus, skin and stomach cancer. The most frequent 
variant was the missense c.215C>G variant, found in 17 cases 
of CGC (6 ALT and 11 HET) and 29 EOGC cases (17 ALT 
and 12 HET), and was also present in patients with hereditary 
cancer predisposing syndrome and Li‑Fraumeni syndrome. 
Based on the COSMIC database, it was found in the large 
intestine and soft tissue cancers, but also in the stomach 
according to the International Cancer Genome Consortium.
Immunohistochemistry staining of CHEK2 and p‑CHEK2 
proteins. The analyzed group encompassed 196 patients, 89 
with CGC and 107 with EOGC (Table IV). The first approach 
was to compare the results from immunohistochemical 
staining in EOGCs and CGC cases. Two categories, high and 
low expression, were distinguished. Differential expression in 
the cytoplasmic CHEK2 and nuclear‑phosphorylated CHEK2 
(P<0.001 and P=0.011, respectively) was statistically signifi‑
cant between the analyzed subgroups. The high expression of 
CHEK2 in the cytoplasm was predominant in the CGC subtype, 
where it was observed in 63% of cases. Phospho‑CHEK2 
was highly expressed in the nuclei of CGC in 53%, whereas 
in EOGC, it was observed in only 34% of samples. The 
differences in the nuclear CHEK2 (CHEK2‑nucleus) and 
cytoplasmic phosphorylated CHEK2 (phospho‑CHEK2‑ 
cytoplasmic) expression patterns between CGC and EOGC 
were not significant (P=0.178 and P=0.133 respectively).
Based on the result that nuclear CHEK2 expression was 
upregulated in both subtypes of GC, this parameter was used 
to distinguish a subgroup of samples with high nuclear CHEK2 
expression, the ‘CHEK2‑nucleus high subgroup’, and compared 
with the other parameters (Table V). In the CHEK2‑nucleus 
high subgroup, there was a statistically significant difference 
Table III. Presentation of variants detected in TP53 gene in EOGC (n=35) and CGC (n=18) cases.
Variant type Protein change Molecular consequence Exon CGC mutations EOGC mutations
c.1129A>C p. Thr377Pro Missense variant 11 ‑ 1 HET
c.1014C>T p. Phe338Phe Synonymous variant 10 ‑ 1 HET
c.851_852delCA p. Thr284fs Frameshift variant 8 1 DEL ‑
c.844C>G p. Arg282Gly Missense variant 8 ‑ 1 HET
c.818G>A p. Arg273His Missense variant 8 1 HET ‑
c.734G>A p. Gly245Asp Missense variant 7 1 HET ‑
c.639A>G p. Arg213Arg Synonymous variant 6 3 HET 1 HET
c.586C>T p. Arg196* Nonsense variant 6 1 HET ‑
c.215C>G p. Pro72Arg Missense variant 4 11 HET + 6 ALT 12 HET + 17 ALT
HET, heterozygous; ALT, alternative homozygous (identical mutation of both paternal and maternal alleles); DEL, deletion; GC, gastric cancer; 
EOGC, early‑onset GC; CGC, conventional GC.
Table II. Presentation of variants identified in CHEK2 gene in EOGC (n=35) and CGC (n=18) cases.
Variant type Protein change Molecular consequence Exon CGC mutations EOGC mutations
c.1741G>T p. Val581Leu Missense variant 16 ‑ 1 HET
c.1246A>G p. Lys416Glu Missense variant 12 3 HET 2 HET
c.1245C>T p. Ser415Ser Synonymous variant 12 3 HET 2 HET
c.252A>G p. Glu84Glu Synonymous variant 2 3 HET 2 HET
c.319+379A>G ‑ Intron variant 2 7 HET + 10 ALT 12 HET + 18 ALT
HET, heterozygous; ALT, alternative homozygous (identical mutation of both paternal and maternal alleles); CHEK2, checkpoint kinase 2; 
GC, gastric cancer; EOGC, early‑onset GC; CGC, conventional GC.
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between the expression of phospho‑CHEK2 in the nucleus 
(phospho‑CHEK2‑nucleus) between CGC and ECOG 
(P=0.002); in CGC, phospho‑CHEK2 in the nucleus was 
upregulated in 64% of cases whereas in EOGCs it was only 
upregulated only in 39% cases. The levels of cytoplasmic 
CHEK2 expression (CHEK2‑cytoplasmic) also significantly 
varied in the two subtypes of GC (P<0.001). In CGC cyto‑
plasmic CHEK2 was high in 77% of cases, whereas in EOGC 
it was only upregulated in 39% of the patients. Expression of 
phospho‑CHEK2 was significantly higher in CGC compared 
with EOGC (P=0.029). The remaining subgroup of low nuclear 
expression of CHEK2 (CHEK2‑nucleus‑low) was analyzed; 
however, none of the evaluated parameters were considered to 
be significantly associated.
Immunohistochemical staining of p53. The analyzed group on 
which p53 staining was performed consisted of 181 patients, 
90 with CGC and 91 with EOGC (Table VI). Staining results 
for p53 protein in both subtypes of GC were compared. Two 
scoring criteria, positive and negative, were used for p53 
expression assessment. Differential expression in the p53‑posi‑
tive and p53‑negative was statistically significant between the 
two groups (P=0.029). The expression of p53 was higher in 
the CGC group, where it was observed in 49% of cases. The 
methodology and results of the p53 staining was previously 
published by Milne et al (24).
The EOGC p53‑positive and CGC p53‑positive param‑
eters were compared with subgroups of samples with 
CHEK2‑nucleus and CHEK2‑cytoplasmic, phosphorylated 
and non‑phosphorylated, and high vs. low expression patterns, 
respectively (Table VII). There was a statistically significant 
difference between the expression of CHEK2‑cytoplasmic 
high and low, and the EOGC p53‑positive and CGC 
p53‑positive patients (P=0.002). CHEK2‑cytoplasmic was 
highly expressed in the CGC p53‑positive group (68%), 
whereas 72% of the EOGC p53‑positive patients had low 
CHEK2‑cytoplasmic expression. The remaining subgroups 
in Table VII were analyzed but none of the parameters were 
found to be significantly different between the subgroups.
Table IV. Comparison of nuclear and cytoplasmic CHEK2 and p‑CHEK2 expression in CGC (n=89) and EOGC (n=107) samples.
 
Expression EOGC, n (%) CGC, n (%) P‑value
 
CHEK2‑nucleus high 93 (87) 70 (79) 0.178
CHEK2‑nucleus low 14 (13) 19 (21) 
CHEK2‑cytoplasmic high 39 (36) 56 (63) <0.001a
CHEK2‑cytoplasmic low 68 (64) 33 (37) 
p‑CHEK2‑nucleus high 36 (34) 47 (53) 0.011a
p‑CHEK2‑nucleus low 71 (66) 42 (47) 
p‑CHEK2‑cytoplasmic high 29 (27) 34 (38) 0.133
p‑CHEK2‑cytoplasmic low 78 (73) 55 (62) 
 
aP<0.05. p‑CHEK2, phosphorylated checkpoint kinase 2; GC, gastric cancer; EOGC, early‑onset GC; CGC, conventional GC.
 
Table VI. Comparison of p53‑positive and ‑negative expression 
between CGC (n=90) and EOGC (n=91) samples.
p53 expression EOGC, n (%) CGC, n (%) P‑value
p53‑positive 29 (32) 44 (49) 0.029a
p53‑negative 62 (68) 46 (51)
aP<0.05. GC, gastric cancer; EOGC, early‑onset GC; CGC, conven‑
tional GC.
Table V. Comparison of CHEK2 and p‑CHEK2 expression in the nucleus and cytoplasm among the CHEK2‑nucleus high 
subgroup between CGC (n=70) and EOGC (n=93) samples.
 CHEK2‑nucleus high CHEK2‑nucleus high 
Expression subgroup in EOGC, n (%) subgroup in CGC, n (%) P‑value
p‑CHEK2‑nucleus high 36 (39) 45 (64) 0.002a
p‑CHEK2‑nucleus low 57 (61) 25 (36) 
CHEK2‑cytoplasmic high 36 (39) 54 (77) <0.001a
CHEK2‑cytoplasmic low 57 (61) 16 (23) 
p‑CHEK2‑cytoplasmic high 26 (28) 32 (46) 0.029a
p‑CHEK2‑cytoplasmic low 67 (72) 38 (54) 
aP<0.05. p‑CHEK2, phosphorylated checkpoint kinase 2; GC, gastric cancer; EOGC, early‑onset GC; CGC, conventional GC.
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The EOGC p53‑negative and CGC p53‑negative subgroups 
were compared with CHEK2‑nucleus and CHEK2‑cytoplasmic, 
both phosphorylated and non‑phosphorylated, high and low 
expression, respectively (Table VIII). The EOGC p53‑nega‑
tive and CGC p53‑negative patients had a significantly 
different CHEK‑2 cytoplasmic expression pattern (P=0.031). 
CHEK2‑cytoplasmic expression was low in EOGC p53‑nega‑
tive patients (66%), whereas high expression was found in 57% 
of CGC p53‑negative patients. Phospho‑CHEK2‑cytoplasmic 
low expression was predominant in the EOGC p53‑negative 
group (76%), and high expression was observed in the CGC 
p53‑negative group (P=0.033). The other groups in Table VIII 
were analyzed; however, none of the assessed parameters were 
statistically significant.
Correlation between the genetic alterations of CHEK2 
and TP53 genes and their protein expression levels. Next, 
the EOGC and CGC cases were compared for the different 
mutation status for SNPs most frequently occurring among 
the analyzed groups in both genes: CHEK2 and TP53, and 
their protein expression levels (Table SIII). Correlations 
between mutations in CHEK2: c.319+379A>G, c.252A>G, 
c.1246A>G, c.1245C>T and CHEK2 protein expression 
in the nucleus and cytoplasm both in the phosphorylated 
and non‑phosphorylated forms was compared. There was a 
statistically significant correlation between occurrence of the 
c.319+379A>G alteration in both CGC and EOGC subtypes 
and phospho‑CHEK2‑nucleus expression levels (P=0.003). 
The expression of phospho‑CHEK2‑nucleus was higher in the 
CGC c.319+379A>G group (82% of cases). Between CGC and 
EOGC with two SNPs in TP53 gene: c.215C>G, c.639A>G and 
p53‑positive and negative staining, there was no statistically 
significant correlations.
Discussion
The primary function of CHEK2 is suppressing tumor 
growth, and exhibits proapoptotic and mitotic functions. 
The association between changes in CHEK2 gene expres‑
sion and cancer risk development have been demonstrated 
in numerous case‑controlled studies (34‑36). The CHEK2 
gene encodes a serine/threonine kinase (CHEK2), which is 
activated by ATM, following mobilization of the cascade 
of DNA damage response molecules to double‑stranded 
breaks. Additionally, CHEK2 is widely phosphorylated at 
Thr68, resulting in its activation, particularly during the 
development of precancerous lesions and in the progression 
of cancer (37).
Table VII. Comparison of high and low CHEK2 and p‑CHEK2 expression in the nucleus and cytoplasm among EOGC 
p53‑positive (n=29) and CGC p53‑positive (n=44) subgroups.
Expression EOGC p53‑positive, n (%) CGC p53‑positive, n (%) P‑value
CHEK2‑nucleus high 27 (93) 38 (86) 0.604
CHEK2‑nucleus low 2 (7)   6 (14) 
CHEK2‑cytoplasmic high   8 (28) 30 (68) 0.002a
CHEK2‑cytoplasmic low 21 (72) 14 (32) 
p‑CHEK2‑nucleus high 10 (34) 24 (55) 0.149
p‑CHEK2‑nucleus low 19 (66) 20 (45) 
p‑CHEK2‑cytoplasmic high   5 (17) 14 (32) 0.264
p‑CHEK2‑cytoplasmic low 24 (83) 30 (68) 
aP<0.05. p‑CHEK2, phosphorylated checkpoint kinase 2; GC, gastric cancer; EOGC, early‑onset GC; CGC, conventional GC.
Table VIII. Comparison of high and low CHEK2 and p‑CHEK2 expression in the nucleus and cytoplasm among EOGC 
p53‑negative (n=62) and CGC p53‑negative (n=46) subgroups.
Expression  EOGC p53‑negative, n (%) CGC p53‑negative, n (%) P‑value
CHEK2‑nucleus high 53 (85) 33 (72) 0.131
CHEK2‑nucleus low   9 (15) 13 (28) 
CHEK2‑cytoplasmic high 21 (34)  26 (57) 0.031a
CHEK2‑cytoplasmic low 41 (66) 20 (43) 
p‑CHEK2‑nucleus high 20 (32) 23 (50) 0.096
p‑CHEK2‑nucleus low 42 (68) 23 (50) 
p‑CHEK2‑cytoplasmic high 15 (24) 21 (46) 0.033a
p‑CHEK2‑cytoplasmic low 47 (76) 25 (54) 
aP<0.05. p‑CHEK2, phosphorylated checkpoint kinase 2; GC, gastric cancer; EOGC, early‑onset GC; CGC, conventional GC.
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In the Polish population, three founder alleles were found: 
A missense substitution of an isoleucine for a threonine in 
exon 3: I157T and two alterations that truncate the CHEK2 
protein: IVS2+1G>A in exon 3 and 1100delC in exon 10, all of 
which have been previously investigated with regard to their 
association with predisposition to GC (16).
Li and Stern (38) found that prior to DNA damage, CHEK2 
is associated with chromatin, and irradiation or topoisomerase 
inhibitors decrease this association. They observed that 
phospho‑CHEK2 was released from chromatin following 
DNA damage, and accumulated in the soluble cytoplasmic 
and soluble nuclear fraction. CHEK2 in human cells exposed 
to DNA‑damaging agents resulted in immediate redistribu‑
tion of the activated CHEK2 throughout the nucleus, rapidly 
spreading the checkpoint arrest signal from localized sites of 
DNA damage to the soluble mobile proteins, such as Cdc25 
or p53 (34). Ćmielová et al (39) showed increased levels of 
phospho‑CHEK2 in the cytoplasmic fraction after 24 and 48 h 
of mitoxantrone treatment. In the present study, only a weak, 
insignificant signal was observed in the nuclear fraction at the 
same time points.
The reports of the subcellular distribution of CHEK2 
are inconsistent and the redistribution of CHEK2 after DNA 
damage is very poorly described. An improved understanding 
of the DNA damage response and protein distribution in 
the cells may assist in improving the efficiency of treatment 
of several types of cancer and may highlight specific novel 
therapeutic targets.
Sequencing results revealed 5 different SNPs within the 
studied group of patients. Variants c.1246A>G (missense 
variant), c.1245C>T (synonymous variant) and c.252A>G 
(synonymous variant) were similarly distributed between the 
subgroups. Amongst the SNPs detected, 3 were HET in CGC 
and 2 were HET in EOGC. Interestingly, the intron variant 
c.319+379A>G was present in a high number of cases; 94% 
of CGCs and 86% EOGCs cases. Only variant c.252A>G has 
been previously shown to be associated with several types of 
cancer, when searching NCBI ClinVar database. However, 
in reference to GC, all the listed SNPs seem to be very rare 
and thus far, have not been broadly described. Interestingly, 
the intron variant c.319+379A>G, detected in the present 
study, was previously shown to be associated with esophageal 
squamous cell carcinoma risk, as reported by Li et al (40).
The tumor suppressor gene TP53 is one of the most regu‑
larly mutated genes in human cancers, and TP53 alterations are 
present in ~77% of stomach cancers (41). Mutations of TP53 
have been detected in the early stages of gastric carcinoma, 
and their frequency increases as the tumor progressed (42). 
TP53 has been termed ‘the guardian of the genome’ (41). 
Genomic instability causes genetic variability and accelerates 
the rate at which a cell acquires and accumulates mutations, 
which may underlie the initiation of tumorigenesis (43). In the 
present study, 9 different genetic alterations of the TP53 gene 
were detected. Most of these occurred sporadically; however, 
variant c.215C>G was present in 17 cases of CGC (6 ALT and 
11 HET) and 29 cases of EOGC cases (17 ALT and 12 HET), 
whereas variant c.639A>G was present in 3 CGC cases and 
1 EOGC cases (all HET). The clinical significance of the 
detected variants was assessed using dbSNP and ClinVar. 
Most of these were associated with the Li‑Fraumeni syndrome 
and hereditary cancer predisposing syndrome. According to 
COSMIC, five of the detected variants were previously shown 
to be associated with stomach cancer (c.844C>G, c.818G>A, 
c.734G>A, c.586C>T and c.215C>G). In the present study, it 
was demonstrated that the TP53 mutations may accumulate 
over a very long period of time (lifetime) (44). With aging, 
genetic damage may increase, increasing the importance of 
the function of TP53, and therefore making an individual more 
vulnerable to loss of function mutations.
Immunohistochemistry analysis may have additional value 
for the assessment of the ATM>CHEK2>p53 pathway. When 
CHEK2 is phosphorylated at Thr68, it is activated. Therefore, 
expression of the phosphorylated protein may be used as a 
potential marker of active CHEK2 status (45). The constitutive 
activation of the DNA damage checkpoint pathway may be 
associated with an increased level of p53 alterations in cancer, 
taking into consideration that p53 is a downstream target 
of ATM and CHEK2. The immunohistochemical analyses 
performed in the present study included analysis of cytoplasmic 
and nuclear expression of CHEK2 and phospho‑CHEK2.
The levels and distribution of expression of these proteins 
appeared to vary between CGC and EOGC. Interestingly, 
the levels of p‑CHEK2 increased with age, and a statistical 
difference between the two subtypes with regard to nuclear 
Figure 2. Differences between early‑onset gastric cancer and conven‑
tional gastric cancer with respect to CHEK2 and p53 staining. p‑CHEK2, 
phosphorylated checkpoint kinase 2.
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p‑CHEK2 expression was observed. Additionally, high nuclear 
CHEK2 expression was also more prevalent in CGC, following 
stratification based on levels of nuclear CHEK2 expression. 
Cytoplasmic phospho‑CHEK2 expression was increased. 
The phosphorylated forms of both CHEK2 types may be an 
indicator of GC development. The levels of CHEK2 protein 
in the nuclei was elevated in both subtypes of GC, and this 
outcome supports further study into the potential therapeutic 
value of CHEK2.
p53 staining was performed on 181 tumor samples, in both 
age dependent subtypes of GC; expression of the p53 protein 
increased with age. Immunohistochemistry analysis of p53 
may explain the biology of the tumor. Multiple studies have 
used immunohistochemistry analysis to assess p53 expression. 
In lung cancer, a meta‑analysis showed that positive immuno‑
histochemistry staining of p53 may be used as a prognostic 
biomarker (46). The results of the present study showed that 
p53 expression could be used to distinguish age dependent 
onset of GC.
The EOGC p53‑positive and CGC p53‑positive groups 
were compared based on phosphorylation of CHEK2. 
There was a statistically significant difference between 
the expression of CHEK2‑cytoplasmic high and low, and 
the EOGC p53‑positive and CGC p53‑positive patients. 
The expression of CHEK2 in the cytoplasm was increased 
(68%) in the CGC p53‑positive group. Statistically important 
differences between CHEK2‑cytoplasmic high and low, 
and the EOGC and CGC p53‑negative patients were also 
observed. CHEK2‑cytoplasmic expression was increased 
in CGC p53‑negative patients (57%), and its expression 
was higher in the CGC p53‑positive subgroup (68%). 
Phospho‑CHEK2‑cytoplasmic was also higher amongst the 
CGC TP53‑negative group. Together, these results suggests a 
link between the expression of p53 and CHEK2 cytoplasmic 
proteins in GC development based on age. Fig. 2 summa‑
rizes the primary differences between EOGC and CGC with 
respect to CHEK2 and p53 staining.
Non‑coding regions possess regulatory functions for the 
coding regions. Thus coding regions are the primary actors, 
but their function is regulated by non‑coding regions. Thus 
any modifications to the non‑coding may have an impact on 
the expression and regulation of the expressed genes. There 
was a statistically significant correlation between occurrence 
of the c.319+379A>G intronic alteration in both CGC and 
EOGC subtypes and phospho‑CHEK2‑nuclear expression, 
which increased with age. 
The present study has some limitations. First, the number 
of biopsies from patients was a limiting factor. The selected 
subgroups were small, and thus it is difficult to observe the 
differences in SNP frequencies in the CHEK2 gene. Use of 
a benign gastric disease control group may better allow for 
determination of whether the protein expression of these 
two genes may be used as biomarkers of early gastric cancer 
development. In vitro studies are required to determine the 
functional effects of the detected SNPs in more detail. It is also 
probable that different allele frequency amongst individuals 
of different ethnicities may have an impact on the obtained 
data. Thus, a more diverse cohort may allow for identification 
of differences in frequencies of SNPs in different populations 
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